Drug Trial Radar · NCT04638829
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Mar 15, 2021
Primary completion
Jan 3, 2024
Study completion Jan 3, 2024
Sponsor
- Lead sponsor
- Sobi, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
Conditions
- Immune Thrombocytopenia
Interventions
Avatrombopag Oral TabletDrug
Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability (Adverse Events)Time frame: Screening through Day 90 or End of Study
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Sobi Site 110
Tucson, Arizona
Sobi Site 119
Whittier, California
Sobi Site 123
Washington D.C., District of Columbia
Sobi Site 129
Miami, Florida
Sobi Site 120
Ocala, Florida
Sobi Site 125
St. Petersburg, Florida
Sobi Site 118
Tampa, Florida
Sobi Site 126
Chicago, Illinois
Sobi Site 109
Peoria, Illinois
Sobi Site 124
New Orleans, Louisiana
Sobi Site 101
Bethesda, Maryland
Sobi Site 103
Lincoln, Nebraska
Sobi Site 121
Chapel Hill, North Carolina
Sobi Site 116
Greenville, North Carolina
Sobi Site 128
Cleveland, Ohio
Sobi Site 127
Philadelphia, Pennsylvania
Sobi Site 102
York, Pennsylvania
Sobi Site 104
Rock Hill, South Carolina
Sobi Site 113
Dallas, Texas
Sobi Site 108
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.